2399-66-8

Basic information

• Product Name: 1-benzoylpyrrolidin-2-one
• Synonyms: 1-Benzoyl-2-pyrrolizinone;1-benzoyl-2-Pyrrolidinone
• CAS NO: 2399-66-8
• Molecular Formula: C₁₁H₁₁NO₂
• Molecular Weight: 189.21
• Mol File: 2399-66-8.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 346°Cat760mmHg
• Flash Point: 161.1°C
• Appearance: /
• Density: 1.234g/cm³
• Vapor Pressure: 5.91E-05mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-benzoylpyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzoylpyrrolidin-2-one(2399-66-8)
• EPA Substance Registry System: 1-benzoylpyrrolidin-2-one(2399-66-8)

Safety Data

• Hazardous Substances Data: 2399-66-8(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Tetrahedron, 35, p. 759, 1979 DOI: 10.1016/0040-4020(79)80092-7

InChI:InChI=1/C11H11NO2/c13-10-7-4-8-12(10)11(14)9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2

Upstream product

• 616-45-5 2-pyrrolidinon 
• 98-88-4 benzoyl chloride 
• 93-97-0 benzoic acid anhydride 
• 70-11-1 α-bromoacetophenone 
• 100-51-6 benzyl alcohol 
• 100-52-7 benzaldehyde 
• 5874-58-8 N-(benzoyl)-L-proline 
• 3389-54-6 n-benzoylpyrrolidine 
• 88-12-0 1-ethenyl-2-pyrrolidinone 
• 195719-48-3 N-benzoylproline 
• 5291-77-0 1-benzyl-2-pyrrolidone 
• 35340-63-7 3-benzoylaminobutanoic acid 
• 65-85-0 benzoic acid 

Downstream Products

• 2000-59-1 5-amino-2-oxo-valeric acid 
• 958462-15-2 (3E)-1-benzoyl-3-(dimethylamino)methylidenepyrrolidin-2-one 
• 958462-21-0 N-[2-(5-hydroxy-1H-pyrazol-4-yl)ethyl]benzamide 
• 958462-22-1 N-[2-(5-hydroxy-1-methyl-1H-pyrazol-4-yl)ethyl]benzamide 
• 958462-23-2 N-{2-[5-hydroxy-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]ethyl}benzamide 
• 958462-24-3 N-[2-(1-benzyl-5-hydroxy-1H-pyrazol-4-yl)ethyl]benzamide 
• 958462-25-4 N-[2-(1-cyclohexyl-5-hydroxy-1H-pyrazol-4-yl)ethyl]benzamide 
• 958462-26-5 N-[2-(5-hydroxy-1-phenyl-1H-pyrazol-4-yl)ethyl]benzamide 
• 958462-27-6 4-[4-(2-benzamidoethyl)-5-hydroxy-1H-pyrazol-1-yl]benzoic acid 
• 958462-28-7 N-{2-[1-(3-chlorophenyl)-5-hydroxy-1H-pyrazol-4-yl]ethyl}benzamide 
• 958462-29-8 N-{2-[1-(4-chlorophenyl)-5-hydroxy-1H-pyrazol-4-yl]ethyl}benzamide 
• 958462-30-1 N-{2-[5-hydroxy-1-(3-methoxyphenyl)-1H-pyrazol-4-yl]ethyl}benzamide 
• 958462-31-2 N-{2-[5-hydroxy-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]ethyl}benzamide 
• 958462-32-3 N-{2-[3-oxo-2-(pyridin-2-yl)-2,3-dihydro-1H-pyrazol-4-yl]ethyl}benzamide 

Relevant articles and documents

Oxidation of N-acyl-pyrrolidines to imides with CrO3·3,5- dimethylpyrazole

N-Acyl-pyrrolidones are easily obtained by treatment of N-acyl- pyrrolidines with CrO33,5-dimethylpyrazole complex (CrO33,5-DMP) at room temperature.

Zirconium-catalysed N-acylation of lactams using unactivated carboxylic acids

A large number of chemicals including surfactants, nootropic drugs and pesticides contain an N-acylated lactam moiety in their molecular structure. In this work, the direct, catalytic N-acylation of a number of lactams with various unactivated carboxylic

Carbazole-containing amides and ureas: Discovery of cryptochrome modulators as antihyperglycemic agents

A series of novel carbazole-containing amides and ureas were synthesized. A structure–activity relationship study of these compounds led to the identification of potent cryptochrome modulators. Based on the desired pharmacokinetic/pharmacodynamic parameters and the results of efficacy studies in db/db mice, compound 50 was selected for further profiling.

CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.